How does rofecoxib’s selectivity reduce stomach (GI) damage?
Rofecoxib is designed to be more selective for COX-2 than COX-1. That matters because COX-1 activity in the stomach helps protect the GI lining by supporting mechanisms like mucus and bicarbonate production and maintaining normal tissue defenses. When a drug inhibits COX-1 strongly, those protective functions drop, increasing the risk of stomach irritation and ulcers. By preferentially inhibiting COX-2, rofecoxib aims to reduce the extent of COX-1 inhibition, so the stomach’s protective COX-1–dependent processes are less affected, which minimizes GI damage compared with non-selective COX inhibitors.
What’s the mechanism behind COX-1 vs COX-2 in the GI tract?
COX-1 is the dominant isoform involved in routine gastric protection. COX-2 is more associated with inflammation and pain signaling in many tissues. Non-selective NSAIDs suppress both COX-1 and COX-2, which can both reduce inflammation and also interfere with the protective “maintenance” role of COX-1 in the stomach. Selectivity for COX-2 reduces that tradeoff by sparing COX-1 more.
Why does this still leave some GI risk?
Even with COX-2 selectivity, rofecoxib is not a perfect COX-1 sparer. At higher doses or in certain conditions, COX-2 selectivity can be less complete, and prostaglandin pathways can still be affected. That means stomach side effects can be reduced, but not always eliminated, especially with other risk factors such as prior ulcer disease or concomitant use of other ulcer-raising medicines.
How does this compare with non-selective NSAIDs?
Non-selective NSAIDs reduce both COX-1 and COX-2, which more directly removes gastric protection and is more strongly linked to GI irritation, bleeding, and ulcer formation. Rofecoxib’s COX-2–biased action is intended to keep COX-1 protection closer to normal, lowering the likelihood of those outcomes relative to traditional non-selective NSAIDs.